These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16955198)

  • 41. Combination biologic treatment of refractory psoriasis and psoriatic arthritis.
    Cuchacovich R; Garcia-Valladares I; Espinoza LR
    J Rheumatol; 2012 Jan; 39(1):187-93. PubMed ID: 22210681
    [No Abstract]   [Full Text] [Related]  

  • 42. Adalimumab therapy of psoriasis and psoriatic arthritis in a patient with cirrhosis of the liver.
    Piel S; Dissemond J
    J Am Acad Dermatol; 2008 Nov; 59(5 Suppl):S117-8. PubMed ID: 19119119
    [No Abstract]   [Full Text] [Related]  

  • 43. [Biologics in the treatment of psoriasis].
    Dissemond J; Grabbe S
    MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concurrent development of psoriatic arthritis, drug-induced interstitial pneumonia, and increased anti-nuclear antibodies in a patient with psoriasis vulgaris undergoing adalimumab treatment.
    Yasuda M; Morimoto N; Yonemoto Y; Sunaga N; Ishikawa O
    Eur J Dermatol; 2019 Feb; 29(1):81-82. PubMed ID: 30530442
    [No Abstract]   [Full Text] [Related]  

  • 45. Safety and efficacy of dual tyrosine kinase 2 inhibitor and monoclonal antibody therapy for psoriasis and psoriatic arthritis.
    Guénin S; Andrews E; Lebwohl MG
    Br J Dermatol; 2024 Feb; 190(3):451-453. PubMed ID: 38011328
    [No Abstract]   [Full Text] [Related]  

  • 46. Efalizumab-associated papular psoriasis.
    Hassan AS; Simon D; Simon HU; Braathen LR; Yawalkar N
    Arch Dermatol; 2007 Jul; 143(7):900-6. PubMed ID: 17638735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study.
    Gisondi P; Giglio MD; Girolomoni G
    J Dermatolog Treat; 2006; 17(3):172-5. PubMed ID: 16854760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.
    Nikas SN; Voulgari PV; Takalou IP; Katsimbri P; Drosos AA
    Ann Rheum Dis; 2005 Nov; 64(11):1665-7. PubMed ID: 16227426
    [No Abstract]   [Full Text] [Related]  

  • 49. Efalizumab-induced autoimmune pancytopenia.
    Tom WL; Miller MD; Hurley MY; Suneja T; Kudva G; Leonardi CL; Obadiah JM
    Br J Dermatol; 2006 Nov; 155(5):1045-7. PubMed ID: 17034539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Cutaneous pseudolymphoma with two types of anti-TNFα: a class effect?].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2012 Oct; 139(10):695-6. PubMed ID: 23122389
    [No Abstract]   [Full Text] [Related]  

  • 51. Successful infliximab therapy of psoriasis vulgaris and psoriatic arthritis in a patient with cirrhosis.
    Lehnen M; Franckson T; Knab J; Hoeft D; Grabbe S; Dissemond J
    Br J Dermatol; 2005 Jul; 153(1):212-4. PubMed ID: 16029357
    [No Abstract]   [Full Text] [Related]  

  • 52. A host of novel agents for treating psoriasis, psoriatic arthritis stir interest.
    Lamberg L
    JAMA; 2003 Jun; 289(21):2779-80, 2783. PubMed ID: 12783895
    [No Abstract]   [Full Text] [Related]  

  • 53. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
    Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
    Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Our experience with infliximab in reclacitrant cases of psoriasis].
    Pereiro M; González-Vilas D; Sánchez-Aguilar D; Toribio J
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():43-7. PubMed ID: 19080991
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
    Kamili QU; Miner A; Hapa A; Menter A
    J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab.
    Bartke U; Venten I; Kreuter A; Gubbay S; Altmeyer P; Brockmeyer NH
    Br J Dermatol; 2004 Apr; 150(4):784-6. PubMed ID: 15099388
    [No Abstract]   [Full Text] [Related]  

  • 57. Tumor necrosis factor (TNF) inhibitors revolutionalized therapy for both psoriasis and psoriatic arthritis. Foreword.
    Gottlieb AB
    Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S3-4. PubMed ID: 24777570
    [No Abstract]   [Full Text] [Related]  

  • 58. Case reports: practical experience with efalizumab in hand and foot psoriasis.
    Cohen DJ; Scherschun L
    J Drugs Dermatol; 2007 Dec; 6(12):1224-30. PubMed ID: 18189064
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.
    Costanzo A; Peris K; Talamonti M; Di Cesare A; Fargnoli MC; Botti E; Chimenti S
    Br J Dermatol; 2007 Apr; 156 Suppl 2():17-23. PubMed ID: 17371319
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Collodion-like membrane in a newborn exposed to infliximab.
    Offiah M; Brodell RT; Campbell LR; Wyatt JP
    J Am Acad Dermatol; 2014 Jul; 71(1):e22-3. PubMed ID: 24947707
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.